DR. MARK H TUSZYNSKI, M.D./PH.D
Neurology at Gilman Dr, La Jolla, CA
License number
California G56665
Category
Neurology
Type
Neurology
Address
Address
9500 Gilman Dr, La Jolla, CA 92093
Phone
(858) 534-8857
(858) 534-5220 (Fax)
(858) 534-5220 (Fax)
Professional information
Mark Henry Tuszynski, San Diego CA
Specialties:
Neurology, Spinal Cord Injury Medicine
Work:
Va San Diego Healthcare System
3350 La Jolla Village Dr, San Diego, CA 92161 Perlman Medical Offices
9350 Campus Point Dr, La Jolla, CA 92037 University of California at San Diego
9500 Gilman Dr, La Jolla, CA 92093
3350 La Jolla Village Dr, San Diego, CA 92161 Perlman Medical Offices
9350 Campus Point Dr, La Jolla, CA 92037 University of California at San Diego
9500 Gilman Dr, La Jolla, CA 92093
Education:
University of Minnesota, Twin Cities (1983)
Dr. Mark H Tuszynski, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
UCSD Shiley Marcos Alzheimers
8950 Villa La Jolla Dr STE 129, La Jolla 92037
(858) 622-5800 (Phone)
8950 Villa La Jolla Dr STE 129, La Jolla 92037
(858) 622-5800 (Phone)
Certifications:
Neurology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Mn Med Sch
Graduated: 1983
U Conn
Cornell U Med Ctr-Ny Hosp
Ucsd
University of Mn Med Sch
Graduated: 1983
U Conn
Cornell U Med Ctr-Ny Hosp
Ucsd
Method For Therapy Of Neurodegenerative Disease Of The Brain
US Patent:
2006005, Mar 9, 2006
Filed:
May 17, 2001
Appl. No.:
10/332306
Inventors:
Mark Tuszynski - La Jolla CA, US
International Classification:
A61K 48/00
US Classification:
424093200
Abstract:
A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified defective, diseased or damaged brain cells. Using a viral vector, the concentration of neurotrophin delivered as part of a neurotrophic composition varies from to neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives form 2.5 μl to 25 μl of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 μm of, a targeted cell, and no more than about 10 mm from another delivery site. Stable in situ neurotrophin expression can be achieved for 12 months, or longer.
Methods For Therapy Of Neurodegenerative Disease Of The Brain
US Patent:
2007003, Feb 15, 2007
Filed:
Oct 17, 2006
Appl. No.:
11/582618
Inventors:
Mark Tuszynski - La Jolla CA, US
International Classification:
A61K 48/00
US Classification:
514044000, 424093200
Abstract:
A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic factor), into a targeted region of the brain (such as the substantia nigra) using a lentiviral expression vector. The neurotrophin is delivered to, or within close proximity of, identified defective, diseased or damaged brain cells. The concentration of neurotrophin delivered as part of a neurotrophic composition varies from 10to 10neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives from 2.5 μl to 25 μl of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 μm of, a targeted cell, and no more than about 10 mm from another delivery site. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated.
Methods For Therapy Of Neurodegenerative Disease Of The Brain
US Patent:
7244423, Jul 17, 2007
Filed:
Dec 29, 2003
Appl. No.:
10/748337
Inventors:
Mark H. Tuszynski - La Jolla CA, US
Assignee:
Regents of the University of California - Oakland CA
International Classification:
A01N 63/00, A61K 48/00
US Classification:
424 932, 514 44, 4353201
Abstract:
A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified defective, diseased or damaged brain cells. Using a viral vector, the concentration of neurotrophin delivered as part of a neurotrophic composition varies from 10to 10neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives from 2. 5 μl to 25 μl of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 μm of, a targeted cell, and no more than about 10 mm from another delivery site. Stable in situ neurotrophin expression can be achieved for 12 months, or longer.
Methods For Therapy Of Neurodegenerative Disease Of The Brain
US Patent:
2007024, Oct 25, 2007
Filed:
Feb 5, 2007
Appl. No.:
11/702936
Inventors:
Mark Tuszynski - La Jolla CA, US
International Classification:
A61K 31/7052, A61P 25/28
US Classification:
514044000
Abstract:
A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified defective, diseased or damaged brain cells. Using a viral vector, the concentration of neurotrophin delivered as part of a neurotrophic composition varies from 10to 10neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives form 2.5 μl to 25 μl of neurotrophic composition delivered slowly, as in over a period of time ranging upward of 10 minutes/delivery site. Each delivery site is at, or within 500 μm of, a targeted cell, and no more than about 10 mm from another delivery site. Stable in situ neurotrophin expression can be achieved for 12 months, or longer.
Methods For Therapy Of Neurodegenerative Disease Of The Brain
US Patent:
2014005, Feb 27, 2014
Filed:
Nov 4, 2013
Appl. No.:
14/071572
Inventors:
Mark H. Tuszynski - La Jolla CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 48/00
US Classification:
514 44 R
Abstract:
A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic factor), into a targeted region of the brain (such as the substantia nigra) using a lentiviral expression vector. The neurotrophin is delivered to, or within close proximity of, identified defective, diseased or damaged brain cells. The concentration of neurotrophin delivered as part of a neurotrophic composition varies from 10to 10neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives from 2.5 μl to 25 μl of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 μm of, a targeted cell, and no more than about 10 mm from another delivery site. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated.
High Aspect Ratio Template And Method For Producing Same
US Patent:
7837913, Nov 23, 2010
Filed:
Aug 10, 2005
Appl. No.:
11/200982
Inventors:
Jeff S. Sakamoto - San Gabriel CA, US
James R. Weiss - Pasadena CA, US
Jean-Pierre Fleurial - Altadena CA, US
Adam Kisor - Burbank CA, US
Mark Tuszynski - La Jolla CA, US
Shula Stokols - La Jolla CA, US
Todd Edward Holt - Vancouver WA, US
David James Welker - Vancouver WA, US
Christopher David Breckon - Ruston WA, US
James R. Weiss - Pasadena CA, US
Jean-Pierre Fleurial - Altadena CA, US
Adam Kisor - Burbank CA, US
Mark Tuszynski - La Jolla CA, US
Shula Stokols - La Jolla CA, US
Todd Edward Holt - Vancouver WA, US
David James Welker - Vancouver WA, US
Christopher David Breckon - Ruston WA, US
Assignee:
California Institute of Technology - Pasadena CA
International Classification:
B29B 17/00, B29B 44/04, B01D 24/00
US Classification:
264 48, 264344, 264 49, 210508, 210505, 424423, 424 937, 428357, 42831151, 623 149, 977896
Abstract:
Millimeter to nano-scale structures manufactured using a multi-component polymer fiber matrix are disclosed. The use of dissimilar polymers allows the selective dissolution of the polymers at various stages of the manufacturing process. In one application, biocompatible matrixes may be formed with long pore length and small pore size. The manufacturing process begins with a first polymer fiber arranged in a matrix formed by a second polymer fiber. End caps may be attached to provide structural support and the polymer fiber matrix selectively dissolved away leaving only the long polymer fibers. These may be exposed to another product, such as a biocompatible gel to form a biocompatible matrix. The polymer fibers may then be selectively dissolved leaving only a biocompatible gel scaffold with the pores formed by the dissolved polymer fibers.
Methods For Modulation Of The Effects Of Aging On The Primate Brain
US Patent:
7157435, Jan 2, 2007
Filed:
Dec 5, 2000
Appl. No.:
09/730790
Inventors:
Mark H. Tuszynski - La Jolla CA, US
Armin Blesch - San Diego CA, US
Armin Blesch - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 43/04, A01N 63/00, C12N 15/00, C12N 15/63, C07H 21/04
US Classification:
514 44, 4353201, 435455, 424 932, 424 9321, 536 235
Abstract:
The invention provides a clinically useful protocol for delivery of recombinant nervous system growth factors into the aging mammalian brain. The invention is particularly useful in tempering and reversing the loss of neurological function in the aging mammalian brain, by (a) correlating loss of cortical fiber density to impairment of neurological function in the normal, aging brain; and (b) providing minimally invasive means by which such losses may be reversed. To these ends, a method is provided by which a growth factor-encoding transgene is delivered to, and expressed in, preselected sites within the brain, to stimulate growth of neurons at, and at a distance from, each delivery site.
Methods For Therapeutic Use Of Brain Derived Neurotrophic Factor In The Entorhinal Cortex
US Patent:
7776320, Aug 17, 2010
Filed:
May 10, 2006
Appl. No.:
11/431436
Inventors:
Mark H. Tuszynski - La Jolla CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01N 63/00, A01N 65/00, A01N 43/04, A61K 48/00, A61K 31/70
US Classification:
424 931, 424 932, 424 9321, 514 44
Abstract:
A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4/5 and NT-3, into the EC. The method is useful in therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease or for normal aging.